Blends of shellac as nanofiber formulations for wound healing
Title | Blends of shellac as nanofiber formulations for wound healing |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Vannuruswamy, G, Rathna, GVenkata Na, Gadgil, BShashikant, Gadad, APanchaksha |
Journal | Journal of Bioactive and Compatible Polymers |
Volume | 30 |
Issue | 5 |
Pagination | 472-489 |
Date Published | SEP |
ISSN | 0883-9115 |
Keywords | drug release and mechanism, nanofibers, Shellac, thermoresponsive, tissue regeneration |
Abstract | Shellac is being used in food, pharmaceutical, and agricultural industries. It is seldom used for biomedical applications due to its poor mechanical property and instability. We designed thermoresponsive shellac-based bioactive nanofiber mats that mimic extracellular matrix to extend their utility in wound healing. Various blend compositions of shellac, gelatin, and poly(N-isopropylacrylamide) enriched with a bioactive agent, nadifloxacin, were prepared and nanofiber mats were fabricated. The morphology of the nanofiber formation was influenced by the concentration of polymer, drug, and polymer blend composition. Polymer-drug interactions and thermal and crystalline properties of nanofiber mats were analyzed. The shellac/gelatin/poly(N-isopropylacrylamide) blend of composition 3%/7%/3% (w/v) was chosen to evaluate in vitro drug release. Release studies recorded slow, constant, and sustained release for 140h. The release kinetics and mechanism confirmed zero-order release with resultant r(2) values greater than 0.99, and the Korsmeyer-Peppas release exponent (n) was slightly higher than 0.8, which indicated that drug diffusion was anomalous or non-Fickian type and drug release followed diffusion involving chain stretching. Indirect cytotoxicity studies recorded insignificant toxicity against normal human fibroblast cells. In vivo studies demonstrated that drug-loaded nanofiber mats were more suitable for faster tissue regeneration as compared to nanofiber mats without drug and commercial nadifloxacin cream. |
DOI | 10.1177/0883911515585180 |
Type of Journal (Indian or Foreign) | Foreign |
Impact Factor (IF) | 1.568 |